Carl read the papersWhat it actually is
CagriSema pairs cagrilintide (a long-acting amylin analogue) with semaglutide (the GLP-1 in Ozempic and Wegovy) in a single fixed-ratio weekly injection.
The logic is mechanical rather than marketing. Amylin and GLP-1 are separate hormones acting on separate receptors — both act on hunger and on food reward, but through partly separate brain circuits, so the effects stack more than they overlap.
How it’s thought to work
- GLP-1 receptor agonism — The semaglutide half — slows gastric emptying, increases satiety, improves glycaemic control.
- Amylin receptor agonism — The cagrilintide half — meal-size reduction through the area postrema and hypothalamus.
- Complementary pathways — The pairing exists because the two mechanisms are additive rather than redundant.
- One weekly injection — Both components are engineered for weekly dosing, so the combination holds a single schedule.
What the research says
REDEFINE 1 (phase 3, n=3,417, 68 weeks) is the trial everything else references. CagriSema produced 22.7% weight reduction — against 16.1% for semaglutide 2.4 mg alone and 11.8% for cagrilintide alone. The combination clearly beat both components. It also landed below the roughly 25% the market had priced in, which is why a strong result was reported as a disappointment. Those are Novo's on-treatment figures; counting everyone who started (the NEJM headline method) it was 20.4% vs 3.0% on placebo. In the later head-to-head REDEFINE 4, CagriSema reached 23.0% vs 25.5% on tirzepatide 15 mg over 84 weeks (same on-treatment method) and missed its goal of showing it was at least as good.
- REDEFINE 1 (phase 3, n=3,417, 68 wks) — 22.7% mean weight reduction.
- Semaglutide alone in the same trial: 16.1%. Cagrilintide alone: 11.8%.
- The combination outperformed either component — the additive premise held.
- GI adverse events dominate, and are heaviest during titration.
Watch: CagriSema explained
Video by Dr. Rob Swanda on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Clinical ladder | Both components escalate together on a fixed ratio, stepping roughly every 4 weeks toward 2.4 mg/2.4 mg |
| Community dose | Reported well below and slower than the trial ladder — a longer climb is the near-universal recommendation |
| Frequency | Once weekly |
| Route | Subcutaneous — abdomen, thigh or upper arm, rotating sites |
| Cycle | The trial ran 68 weeks continuously |
| Community tip | The fixed ratio is the practical catch: you cannot back off the amylin half without also backing off the GLP-1 half. People who want independent control run the two compounds separately. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Appetite / satiety | weekly, both halves escalating together on a long ladder |
| Plateau on a GLP-1 alone | adds a second mechanism rather than more of the first |
| Simplicity over control | one vial, one injection — at the cost of independent dose control |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Subcutaneous, once weekly — abdomen, thigh or upper arm, rotating sites. Both halves are long-acting, so a dose that does not suit you stays with you for days; that is the argument for a slow climb. The fixed ratio means the two components rise and fall together, which is the main practical difference from running them as separate vials. Reconstituted, keep it cold and out of the light.
Stacks it appears in
- It is already a stack — CagriSema is the combination. Adding another GLP-1 on top duplicates the semaglutide half.
- Separate vials instead — Running cagrilintide and semaglutide separately costs an extra injection and buys independent control of each dose.
Sources
- REDEFINE 1, cagrilintide plus semaglutide, NEJM 2025 (PMID 40544433)
- REDEFINE 2 in type 2 diabetes, NEJM 2025 (PMID 40544432)
- Novo Nordisk 6-K: REDEFINE 1 headline results (20 Dec 2024)
- Novo Nordisk 6-K: REDEFINE 4 vs tirzepatide (23 Feb 2026)
- Novo Nordisk press release: CagriSema NDA filed with FDA (18 Dec 2025)
- Novo Nordisk 6-K: H1 2026 financial report (4 Aug 2026)
- REDEFINE 1 design, ClinicalTrials.gov NCT05567796
- Patient Care Online news: REDEFINE 1 short of the 25% expected (20 Dec 2024)
- Amylin in homeostatic and hedonic eating, review, Mol Metab 2018 (PMID 29203236)
- GLP-1 agonist reduces food reward via mesolimbic receptors, J Neurosci 2012 (PMID 22492036)
